Article Text

Download PDFPDF
HLA-B60 and the HLA-B27/HLA-B60 genotype are not risk factors for acute anterior uveitis
  1. Floris A van Gaalen1,
  2. Willem Verduijn2,
  3. Dave L Roelen2,
  4. Tom W J Huizinga1,
  5. Désiree van der Heijde1,
  6. René E M Toes1
  1. 1 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2 Department of Immunohaematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Dr Floris A van Gaalen, Department of Rheumatology, Leiden University Medical Center, C4-R, PO Box 9600, Leiden 2300 R, The Netherlands; f.a.van_gaalen{at}

Statistics from

Ankylosing spondylitis (AS) is the prototypical example of an human leukocyte antigen (HLA) -B27-associated rheumatic disease. Recently, we confirmed that HLA-B60 is also genetic risk factor for AS (OR in meta-analysis 2.2; 95% CI 1.8 to 2.8).1

Moreover, while 18% of AS patients had both HLA-B27 and HLA-B60, this combination of two HLA-alleles in one person (HLA-B27/HLA-B60) was very rare in blood donors (0.4%). As a result, individuals with the HLA-B27/HLA-B60 genotype are at a very high risk of developing AS.1 Acute anterior uveitis (AAU) may complicate AS but is also an HLA-B27-associated disease in itself.2 Given that AAU share clinical and genetic features with AS, we investigated if HLA-B60 is a risk factor for AAU.

Patients were found by retrospective review of …

View Full Text


  • Contributors Conception: FAVG, REMT; Design: FAvG, TWJH, DvdH, REMT; Analysis: FAVG, WV, DLR; Interpretation: FAVG, WV, DLR, TWJH, DvdH, REMT; Drafting the article and revising the article, including the final version: FAVG, WV, DLR, TWJH, DVdH, REMT.

  • Competing interests None.

  • Funding REMT's work is supported by an NWO-ZonMW VICI grant from the Dutch Organization for Scientific Research.

  • Patient consent HLA typing was performed for diagnostic purposes for which all patients gave their consent. This non-interventional, retrospective study was performed in accordance with Dutch patient protection law.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.